Applications of bacteriophages versus phage enzymes to combat and cure bacterial infections: an ambitious and also a realistic application?

Applied Microbiology and Biotechnology

Volumn 102, Issue 6, 2018, Pages 2563-2581

  Maciejewska, Barbara ^a   Olszak, Tomasz ^a   Drulis Kawa, Zuzanna ^a  

^a UNIVERSITY OF WROC AW   (Poland)

Author keywords

Phage enzymes application in treatment; Phage lysins; Phage therapy; Phage borne polysaccharide depolymerases

Indexed keywords

ENZYMES;

ANTIBACTERIALS; BACTERIAL INFECTIONS; CURRENT REGULATIONS; MODE OF ACTION; PHAGE THERAPY; PRODUCT APPLICATIONS; REALISTIC APPLICATIONS; STRUCTURAL ISSUES;

BACTERIOPHAGES;

ANTIBIOTIC AGENT; BACTERIAL ENZYME; ENZYME;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIOPHAGE; BIOFILM; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENZYME SPECIFICITY; ERADICATION THERAPY; HOST RANGE; HUMAN; IMMUNE SYSTEM; LIFE CYCLE; MICROFLORA; NONHUMAN; PHAGE THERAPY; REVIEW; SAFETY; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PROCEDURES;

BACTERIA (MICROORGANISMS);

BACTERIAL INFECTIONS; BACTERIOPHAGES; ENZYMES; HUMANS; PHAGE THERAPY;

EID: 85041923171     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-018-8811-1     Document Type: Review

References (152)

1. Abedon ST (2015) Ecology of anti-biofilm agents II: bacteriophage exploitation and biocontrol of biofilm bacteria. Pharmaceuticals 8:559–589. https://doi.org/10.3390/ph8030559
2. Abedon ST (2016a) Phage therapy dosing: the problem(s) with multiplicity of infection (MOI). Bacteriophage 6:e1220348. https://doi.org/10.1080/21597081.2016.1220348
3. Abedon ST (2016b) Bacteriophage exploitation of bacterial biofilms: phage preference for less mature targets? FEMS Microbiol Lett 363:fnv246. https://doi.org/10.1093/femsle/fnv246
4. Abedon ST (2017) Information phage therapy research should report. Pharmaceuticals 10:43. https://doi.org/10.3390/ph10020043
5. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM (2011) Phage treatment of human infections. Bacteriophage 1:66–85. https://doi.org/10.4161/bact.1.2.15845
6. Alisky J, Iczkowski K, Rapoport A, Troitsky N (1998) Bacteriophages show promise as antimicrobial agents. J Inf Secur 36:5–15
7. Alper T (1954) The inactivation of free bacteriophage by irradiation and by chemical agents. J Gen Microbiol 11:313–324. https://doi.org/10.1099/00221287-11-2-313
8. Argov T, Azulay G, Pasechnek A, Stadnyuk O, Ran-Sapir S, Borovok I, Sigal N, Herskovits AA (2017) Temperate bacteriophages as regulators of host behavior. Curr Opin Microbiol 38:81–87. https://doi.org/10.1016/j.mib.2017.05.002
9. Bansal S, Soni SK, Harjai K, Chhibber S (2014) Aeromonas punctata derived depolymerase that disrupts the integrity of Klebsiella pneumoniae capsule: optimization of depolymerase production. J Basic Microbiol 54:711–720. https://doi.org/10.1002/jobm.201300356
10. Barrow PA, Soothill JS (1997) Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol 5:268–271. https://doi.org/10.1016/S0966-842X(97)01054-8
11. Bonilla N, Rojas MI, Netto Flores Cruz G, Hung S-H, Rohwer F, Barr JJ (2016) Phage on tap—a quick and efficient protocol for the preparation of bacteriophage laboratory stocks. PeerJ 4:e2261. https://doi.org/10.7717/peerj.2261
12. Borysowski J, Weber-Dabrowska B, Górski A (2006) Bacteriophage endolysins as a novel class of antibacterial agents. Exp Biol Med (Maywood) 231:366–377. https://doi.org/10.1177/153537020623100402
13. Briers Y, Volckaert G, Cornelissen A, Lagaert S, Michiels CW, Hertveldt K, Lavigne R (2007) Muralytic activity and modular structure of the endolysins of Pseudomonas aeruginosa bacteriophages φKZ and EL. Mol Microbiol 65:1334–1344. https://doi.org/10.1111/j.1365-2958.2007.05870.x
14. Briers Y, Walmagh M, Lavigne R (2011) Use of bacteriophage endolysin EL188 and outer membrane permeabilizers against Pseudomonas aeruginosa. J Appl Microbiol 110:778–785. https://doi.org/10.1111/j.1365-2672.2010.04931.x
15. Briers Y, Walmagh M, Van Puyenbroeck V, Cornelissen A, Cenens W, Aertsen A, Oliveira H, Azeredo J, Verween G, Pirnay J-P, Miller S, Volckaert G, Lavigne R (2014) Engineered endolysin-based “Artilysins” to combat multidrug-resistant gram-negative pathogens. MBio 5:e01379–e01314. https://doi.org/10.1128/mBio.01379-14
16. Brussaard CPD, Wilhelm SW, Thingstad F, Weinbauer MG, Bratbak G, Heldal M, Kimmance SA, Middelboe M, Nagasaki K, Paul JH, Schroeder DC, Suttle CA, Vaqué D, Wommack KE (2008) Global-scale processes with a nanoscale drive: the role of marine viruses. ISME J 2:575–578. https://doi.org/10.1038/ismej.2008.31
17. Bull JJ, Levin BR, DeRouin T, Walker N, Bloch CA (2002) Dynamics of success and failure in phage and antibiotic therapy in experimental infections. BMC Microbiol 2:35. https://doi.org/10.1186/1471-2180-2-35
18. Carlton RM (1999) Phage therapy: past history and future prospects. Arch Immunol Ther Exp 47:267–274
19. Chan BK, Abedon ST (2012) Phage therapy pharmacology. Phage cocktails. Adv Appl Microbiol 78:1–23. https://doi.org/10.1016/B978-0-12-394805-2.00001-4
20. Chan BK, Abedon ST, Loc-Carrillo C (2013) Phage cocktails and the future of phage therapy. Future Microbiol 8:769–783. https://doi.org/10.2217/fmb.13.47
21. Chan JM, Valencia PM, Zhang L, Langer R, Farokhzad OC (2010) Polymeric nanoparticles for drug delivery. Methods Mol Biol 624:163–175. https://doi.org/10.1007/978-1-60761-609-2_11
22. Chaudhry WN, Concepción-Acevedo J, Park T, Andleeb S, Bull JJ, Levin BR (2017) Synergy and order effects of antibiotics and phages in killing Pseudomonas aeruginosa biofilms. PLoS One 12:e0168615. https://doi.org/10.1371/journal.pone.0168615
23. Cheng Q, Fischetti VA (2007) Mutagenesis of a bacteriophage lytic enzyme PlyGBS significantly increases its antibacterial activity against group B streptococci. Appl Microbiol Biotechnol 74:1284–1291. https://doi.org/10.1007/s00253-006-0771-1
24. Cheng Q, Nelson D, Zhu S, Fischetti VA (2005) Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob Agents Chemother 49:111–117. https://doi.org/10.1128/AAC.49.1.111-117.2005
25. Cisek AA, Dąbrowska I, Gregorczyk KP, Wyżewski Z (2017) Phage therapy in bacterial infections treatment: one hundred years after the discovery of bacteriophages. Curr Microbiol 74:277–283. https://doi.org/10.1007/s00284-016-1166-x
26. Cornelissen A, Ceyssens P-J, T’Syen J, Van Praet H, Noben J-P, Shaburova OV, Krylov VN, Volckaert G, Lavigne R (2011) The T7-related Pseudomonas putida phage φ15 displays virion-associated biofilm degradation properties. PLoS One 6:e18597. https://doi.org/10.1371/journal.pone.0018597
27. D’Herelle F (1931) An address on bacteriophagy and recovery from infectious diseases. Can Med Assoc J 24:619
28. Dabrowska K, Switala-Jelen K, Opolski A, Weber-Dabrowska B, Gorski A (2005) Bacteriophage penetration in vertebrates. J Appl Microbiol 98:7–13. https://doi.org/10.1111/j.1365-2672.2004.02422.x
29. Daniel A, Euler C, Collin M, Chahales P, Gorelick KJ, Fischetti VA (2010) Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 54:1603–1612. https://doi.org/10.1128/AAC.01625-09
30. Debarbieux L, Pirnay JP, Verbeken G, De Vos D, Merabishvili M, Huys I, Patey O, Schoonjans D, Vaneechoutte M, Zizi M, Rohde C (2016) A bacteriophage journey at the European Medicines Agency. FEMS Microbiol Lett 363:fnv225. https://doi.org/10.1093/femsle/fnv225
31. Díez-Martínez R, De Paz HD, García-Fernández E, Bustamante N, Euler CW, Fischetti VA, Menendez M, García P (2014) A novel chimeric phage lysin with high in vitro and in vivo bactericidal activity against Streptococcus pneumoniae. J Antimicrob Chemother 70:1763–1773. https://doi.org/10.1093/jac/dkv038
32. Doehn JM, Fischer K, Reppe K, Gutbier B, Tschernig T, Hocke AC, Fischetti V a, Löffler J, Suttorp N, Hippenstiel S, Witzenrath M (2013) Delivery of the endolysin Cpl-1 by inhalation rescues mice with fatal pneumococcal pneumonia. J Antimicrob Chemother 68:2111–2117. doi: https://doi.org/10.1093/jac/dkt131
33. Domenech M, Garciá E, Moscoso M (2011) In vitro destruction of Streptococcus pneumoniae biofilms with bacterial and phage peptidoglycan hydrolases. Antimicrob Agents Chemother 55:4144–4148. https://doi.org/10.1128/AAC.00492-11
34. Edgar R, Friedman N, Shahar MM, Qimron U (2012) Reversing bacterial resistance to antibiotics by phage-mediated delivery of dominant sensitive genes. Appl Environ Microbiol 78:744–751. https://doi.org/10.1128/AEM.05741-11
35. Entenza JM, Loeffler JM, Grandgirard D, Fischetti VA, Moreillon P (2005) Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats. Antimicrob Agents Chemother 49:4789–4792. https://doi.org/10.1128/AAC.49.11.4789-4792.2005
36. Erez Z, Steinberger-Levy I, Shamir M, Doron S, Stokar-Avihail A, Peleg Y, Melamed S, Leavitt A, Savidor A, Albeck S, Amitai G, Sorek R (2017) Communication between viruses guides lysis-lysogeny decisions. Nature:1–18. https://doi.org/10.1038/nature21049
37. Fenton M, Keary R, McAuliffe O, Ross RP, O’Mahony J, Coffey A (2013) Bacteriophage-derived peptidase CHAPK eliminates and prevents staphylococcal biofilms. Int J Microbiol 2013:625341. https://doi.org/10.1155/2013/625341
38. Fischetti VA (2010) Bacteriophage endolysins: a novel anti-infective to control gram-positive pathogens. Int J Med Microbiol 300:357–362. https://doi.org/10.1016/j.ijmm.2010.04.002
39. Fischetti VA (2005) Bacteriophage lytic enzymes: novel anti-infectives. Trends Microbiol 13:491–496. https://doi.org/10.1016/j.tim.2005.08.007
40. Gervasi T, Horn N, Wegmann U, Dugo G, Narbad A, Mayer MJ (2014) Expression and delivery of an endolysin to combat Clostridium perfringens. Appl Microbiol Biotechnol 98:2495–2505. https://doi.org/10.1007/s00253-013-5128-y
41. Gilmer DB, Schmitz JE, Euler CW, Fischetti VA (2013) Novel bacteriophage lysin with broad lytic activity protects against mixed infection by Streptococcus pyogenes and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 57:2743–2750. https://doi.org/10.1128/AAC.02526-12
42. Gilmer DB, Schmitz JE, Thandar M, Euler CW, Fischetti VA (2017) The phage lysin PlySs2 decolonizes Streptococcus suis from murine intranasal mucosa. PLoS One 12:e0169180. https://doi.org/10.1371/journal.pone.0169180
43. Goldfarb T, Sberro H, Weinstock E, Cohen O, Doron S, Charpak-Amikam Y, Afik S, Ofir G, Sorek R (2015) BREX is a novel phage resistance system widespread in microbial genomes. EMBO J 34:169–183. https://doi.org/10.15252/embj.201489455
44. Goodridge LD (2010) Designing phage therapeutics. Curr Pharm Biotechnol 11:15–27. https://doi.org/10.2174/138920110790725348
45. Gorski A, Wazna E, Dabrowska B-W, Dabrowska K, Switała-Jelen K, Miedzybrodzki R (2006) Bacteriophage translocation. FEMS Immunol Med Microbiol 46:313–319. https://doi.org/10.1111/j.1574-695X.2006.00044.x
46. Górski A, Międzybrodzki R, Borysowski J, Dąbrowska K, Wierzbicki P, Ohams M, Korczak-Kowalska G, Olszowska-Zaremba N, Łusiak-Szelachowska M, Kłak M, Jończyk E, Kaniuga E, Gołaś A, Purchla S, Weber-Dąbrowska B, Letkiewicz S, Fortuna W, Szufnarowski K, Pawełczyk Z, Rogóz P, Kłosowska D (2012) Phage as a modulator of immune responses. Practical implications for phage therapy. Adv Virus Res 83:41–71. https://doi.org/10.1016/B978-0-12-394438-2.00002-5
47. Grandgirard D, Loeffler JM, Fischetti VA, Leib SL (2008) Phage lytic enzyme Cpl-1 for antibacterial therapy in experimental pneumococcal meningitis. J Infect Dis 197:1519–1522. https://doi.org/10.1086/587942
48. Gu J, Xu W, Lei L, Huang J, Feng X, Sun C, Du C, Zuo J, Li Y, Du T, Li L, Han W (2011a) LysGH15, a novel bacteriophage lysin, protects a murine bacteremia model efficiently against lethal methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol 49:111–117. https://doi.org/10.1128/JCM.01144-10
49. Gu J, Zuo J, Lei L, Zhao H, Sun C, Feng X, Du C, Li X, Yang Y, Han W (2011b) LysGH15 reduces the inflammation caused by lethal methicillin-resistant Staphylococcus aureus infection in mice. Bioeng Bugs 2:96–99. https://doi.org/10.4161/bbug.2.2.14883
50. Guariglia-Oropeza V, Helmann JD (2011) Bacillus subtilis σ(V) confers lysozyme resistance by activation of two cell wall modification pathways, peptidoglycan O-acetylation and D-alanylation of teichoic acids. J Bacteriol 193:6223–6232. https://doi.org/10.1128/JB.06023-11
51. Guo M, Feng C, Ren J, Zhuang X, Zhang Y, Zhu Y, Dong K, He P, Guo X, Qin J (2017) A novel antimicrobial endolysin, LysPA26, against Pseudomonas aeruginosa. Front Microbiol 8. https://doi.org/10.3389/fmicb.2017.00293
52. Gupta R, Prasad Y (2011a) P-27/HP Endolysin as antibacterial agent for antibiotic resistant Staphylococcus aureus of human infections. Curr Microbiol 63:39–45. https://doi.org/10.1007/s00284-011-9939-8
53. Gupta R, Prasad Y (2011b) Efficacy of polyvalent bacteriophage P-27/HP to control multidrug resistant Staphylococcus aureus associated with human infections. Curr Microbiol 62:255–260. https://doi.org/10.1007/s00284-010-9699-x
54. Gutiérrez D, Briers Y, Rodríguez-Rubio L, Martínez B, Rodríguez A, Lavigne R, García P (2015) Role of the pre-neck appendage protein (Dpo7) from phage vB_SepiS-phiIPLA7 as an anti-biofilm agent in staphylococcal species. Front Microbiol 6:1315. https://doi.org/10.3389/fmicb.2015.01315
55. Gutiérrez D, Martínez B, Rodríguez A, García P (2012) Genomic characterization of two Staphylococcus epidermidis bacteriophages with anti-biofilm potential. BMC Genomics 13:228. https://doi.org/10.1186/1471-2164-13-228
56. Gutiérrez D, Ruas-Madiedo P, Martínez B, Rodríguez A, García P (2014) Effective removal of staphylococcal biofilms by the endolysin LysH5. PLoS One 9:e107307. https://doi.org/10.1371/journal.pone.0107307
57. Heselpoth RD, Yin Y, Moult J, Nelson DC (2015) Increasing the stability of the bacteriophage endolysin PlyC using rationale-based FoldX computational modeling. Protein Eng Des Sel 28:85–92. https://doi.org/10.1093/protein/gzv004
58. Höltje JV, Mirelman D, Sharon N, Schwarz U (1975) Novel type of murein transglycosylase in Escherichia coli. J Bacteriol 124:1067–1076
59. Jado I, López R, García E, Fenoll A, Casal J, García P, Pallares R, de la Campa AG, Bouza E, Baquero F, Soriano F, Prieto J, Pallarés R, Liñares J, Garau J, Martínez Lacasa J, Latorre C, Pérez-Trallero E, García de Lomas J, Fleites A (2003) Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. J Antimicrob Chemother 52:967–973. https://doi.org/10.1093/jac/dkg485
60. Jennes S, Merabishvili M, Soentjens P, Pang KW, Rose T, Keersebilck E, Soete O, François P-M, Teodorescu S, Verween G, Verbeken G, De Vos D, Pirnay J-P (2017) Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury—a case report. Crit Care 21:129. https://doi.org/10.1186/s13054-017-1709-y
61. Jończyk E, Kłak M, Międzybrodzki R, Górski A (2011) The influence of external factors on bacteriophages—review. Folia Microbiol 56:191–200. https://doi.org/10.1007/s12223-011-0039-8
62. Jun SY, Jang IJ, Yoon S, Jang K, Yu K-S, Cho JY, Seong M-W, Jung GM, Yoon SJ, Kang SH (2017) Pharmacokinetics and tolerance of the phage endolysin-based candidate drug SAL200 after a single intravenous administration among healthy volunteers. Antimicrob Agents Chemother 61:e02629–e02616. https://doi.org/10.1128/AAC.02629-16
63. Jun SY, Jung GM, Yoon SJ, Choi YJ, Koh WS, Moon KS, Kang SH (2014) Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient. Antimicrob Agents Chemother 58:2084–2088. https://doi.org/10.1128/AAC.02232-13
64. Jun SY, Jung GM, Yoon SJ, Oh MD, Choi YJ, Lee WJ, Kong JC, Seol JG, Kang SH (2013) Antibacterial properties of a pre-formulated recombinant phage endolysin, SAL-1. Int J Antimicrob Agents 41:156–161. https://doi.org/10.1016/j.ijantimicag.2012.10.011
65. Jun SY, Jung GM, Yoon SJ, Youm SY, Han H-Y, Lee J-H, Kang SH (2016) Pharmacokinetics of the phage endolysin-based candidate drug SAL200 in monkeys and its appropriate intravenous dosing period. Clin Exp Pharmacol Physiol 43:1013–1016. https://doi.org/10.1111/1440-1681.12613
66. Kim M, Ryu S (2013) Antirepression system associated with the life cycle switch in the temperate Podoviridae phage SPC32H. J Virol 87:11775–11786. https://doi.org/10.1128/JVI.02173-13
67. Krylov V, Shaburova O, Krylov S, Pleteneva E (2012) A genetic approach to the development of new therapeutic phages to fight Pseudomonas aeruginosa in wound infections. Viruses 5:15–53. https://doi.org/10.3390/v5010015
68. Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S, Abedon ST (2010) Phage therapy in clinical practice: Treatment of human infections. Curr Pharm Biotechnol 11:69–86. https://doi.org/10.2174/138920110790725401
69. Labrie SJ, Samson JE, Moineau S (2010) Bacteriophage resistance mechanisms. Nat Rev Microbiol 8:317–327. https://doi.org/10.1038/nrmicro2315
70. Latino L, Midoux C, Hauck Y, Vergnaud G, Pourcel C (2016) Pseudolysogeny and sequential mutations build multiresistance to virulent bacteriophages in Pseudomonas aeruginosa. Microbiol (United Kingdom) 162:748–763. https://doi.org/10.1099/mic.0.000263
71. Latka A, Maciejewska B, Majkowska-Skrobek G, Briers Y, Drulis-Kawa Z (2017) Bacteriophage-encoded virion-associated enzymes to overcome the carbohydrate barriers during the infection process. Appl Microbiol Biotechnol 101:3103–3119. https://doi.org/10.1007/s00253-017-8224-6
72. Letkiewicz S, Miedzybrodzki R, Klak M, Jonczyk E, Weber-Dabrowska B, Gorski A (2010) The perspectives of the application of phage therapy in chronic bacterial prostatitis. FEMS Immunol Med Microbiol 60:99–112. https://doi.org/10.1111/j.1574-695X.2010.00723.x
73. Lim JA, Shin H, Heu S, Ryu S (2014) Exogenous lytic activity of SPN9CC endolysin against gram-negative bacteria. J Microbiol Biotechnol 24:803–811. https://doi.org/10.4014/jmb.1403.03035
74. Lin DM, Koskella B, Lin HC (2017) Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther 8:162. https://doi.org/10.4292/wjgpt.v8.i3.162
75. Loc-Carrillo C, Abedon ST (2011) Pros and cons of phage therapy. Bacteriophage 1:111–114. https://doi.org/10.4161/bact.1.2.14590
76. Loeffler JM, Djurkovic S, Fischetti VA (2003) Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infect Immun 71:6199–6204. https://doi.org/10.1128/IAI.71.11.6199-6204.2003
77. Loeffler JM, Nelson D, Fischetti VA (2001) Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 294:2170–2172. https://doi.org/10.1126/science.1066869
78. Lood R, Raz A, Molina H, Euler CW, Fischetti VA (2014) A highly active and negatively charged Streptococcus pyogenes lysin with a rare d-alanyl-l-alanine endopeptidase activity protects mice against streptococcal bacteremia. Antimicrob Agents Chemother 58:3073–3084. https://doi.org/10.1128/AAC.00115-14
79. Lood R, Winer BY, Pelzek AJ, Diez-Martinez R, Thandar M, Euler CW, Schuch R, Fischetti VA (2015) Novel phage lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model. Antimicrob Agents Chemother 59:1983–1991. https://doi.org/10.1128/AAC.04641-14
80. Łoś M, Węgrzyn G (2012) Pseudolysogeny. Adv Virus Res 82:339–49. https://doi.org/10.1016/B978-0-12-394621-8.00019-4
81. Lu TK, Collins JJ (2007) Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci U S A 104:11197–11202. https://doi.org/10.1073/pnas.0704624104
82. Maciejewska B, Roszniowski B, Espaillat A, Kesik-Szeloch A, Majkowska-Skrobek G, Kropinski AM, Briers Y, Cava F, Lavigne R, Drulis-Kawa Z (2017) Klebsiella phages representing a novel clade of viruses with an unknown DNA modification and biotechnologically interesting enzymes. Appl Microbiol Biotechnol 101:673–684. https://doi.org/10.1007/s00253-016-7928-3
83. Majkowska-Skrobek G, Latka A, Berisio R, Maciejewska B, Squeglia F, Romano M, Lavigne R, Struve C, Drulis-Kawa Z (2016) Capsule-targeting depolymerase, derived from Klebsiella KP36 phage, as a tool for the development of anti-virulent strategy. Viruses 8:324. https://doi.org/10.3390/v8120324
84. Matsushita I, Yanase H (2008) A novel thermophilic lysozyme from bacteriophage phiIN93. Biochem Biophys Res Commun 377:89–92. https://doi.org/10.1016/j.bbrc.2008.09.101
85. Mayer MJ, Narbad A, Gasson MJ (2008) Molecular characterization of a Clostridium difficile bacteriophage and its cloned biologically active endolysin. J Bacteriol 190:6734–6740. https://doi.org/10.1128/JB.00686-08
86. McCallum KL, Laakso DH, Whitfield C (1989) Use of a bacteriophage-encoded glycanase enzyme in the generation of lipopolysaccharide O-side chain deficient mutants of Escherichia coli O9:K30 and Klebsiella O1:K20: Role of O and K antigens in resistance to complement-mediated serum killing. Can J Microbiol 35:994–999. https://doi.org/10.1139/m89-166
87. McCullers JA, Karlström Å, Iverson AR, Loeffler JM, Fischetti VA (2007) Novel strategy to prevent otitis media caused by colonizing Streptococcus pneumoniae. PLoS Pathog 3:e28. https://doi.org/10.1371/journal.ppat.0030028
88. Meng X, Shi Y, Ji W, Meng X, Zhang J, Wang H, Lu C, Sun J, Yan Y (2011) Application of a bacteriophage lysin to disrupt biofilms formed by the animal pathogen Streptococcus suis. Appl Environ Microbiol 77:8272–8279. https://doi.org/10.1128/AEM.05151-11
89. Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S, Adhya S (1996) Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci U S A 93:3188–3192
90. Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, Fortuna W, Letkiewicz S, Szufnarowski K, Pawelczyk Z, Rogoz P, Klak M, Wojtasik E, Gorski A (2012) Clinical aspects of phage therapy. Adv Virus Res 83:73–121. https://doi.org/10.1016/B978-0-12-394438-2.00003-7
91. Mushtaq N, Redpath MB, Luzio JP, Taylor PW (2004) Prevention and cure of systemic Escherichia coli K1 infection by modification of the bacterial phenotype. Antimicrob Agents Chemother 48:1503–1508. https://doi.org/10.1128/AAC.48.5.1503-1508.2004
92. Mushtaq N, Redpath MB, Luzio JP, Taylor PW (2005) Treatment of experimental Escherichia coli infection with recombinant bacteriophage-derived capsule depolymerase. J Antimicrob Chemother 56:160–165. https://doi.org/10.1093/jac/dki177
93. Nau R, Eiffert H (2002) Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 15:95–110. https://doi.org/10.1128/CMR.15.1.95-110.2002
94. Navarro F, Muniesa M (2017) Phages in the human body. Front Microbiol 8:566. https://doi.org/10.3389/fmicb.2017.00566
95. Nelson D, Loomis L, Fischetti VA (2001) Prevention and elimination of upper respiratory colonization of mice by group a streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci U S A 98:4107–4112. https://doi.org/10.1073/pnas.061038398
96. Nelson DC, Schmelcher M, Rodriguez-Rubio L, Klumpp J, Pritchard DG, Dong S, Donovan DM (2012) Endolysins as antimicrobials. In: Advances in Virus Research. 83:299-365. https://doi.org/10.1016/B978-0-12-394438-2.00007-4
97. Oechslin F, Daraspe J, Giddey M, Moreillon P, Resch G (2013) In vitro characterization of PlySK1249, a novel phage lysin, and assessment of its antibacterial activity in a mouse model of Streptococcus agalactiae bacteremia. Antimicrob Agents Chemother 57:6276–6283. https://doi.org/10.1128/AAC.01701-13
98. Oliveira H, Thiagarajan V, Walmagh M, Sillankorva S, Lavigne R, Neves-Petersen MT, Kluskens LD, Azeredo J (2014) A thermostable Salmonella phage endolysin, Lys68, with broad bactericidal properties against gram-negative pathogens in presence of weak acids. PLoS One 9:e108376. https://doi.org/10.1371/journal.pone.0108376
99. Oliveira H, Vilas Boas D, Mesnage S, Kluskens LD, Lavigne R, Sillankorva S, Secundo F, Azeredo J (2016) Structural and enzymatic characterization of ABgp46, a novel phage endolysin with broad anti-gram-negative bacterial activity. Front Microbiol 7:208. https://doi.org/10.3389/fmicb.2016.00208
100. Olszak T, Shneider MM, Latka A, Maciejewska B, Browning C, Sycheva LV, Cornelissen A, Danis-Wlodarczyk K, Senchenkova SN, Shashkov AS, Gula G, Arabski M, Wasik S, Miroshnikov KA, Lavigne R, Leiman PG, Knirel YA, Drulis-Kawa Z (2017) The O-specific polysaccharide lyase from the phage LKA1 tailspike reduces Pseudomonas virulence. Sci Rep 7:16302. https://doi.org/10.1038/s41598-017-16411-4
101. Ormälä A-M, Jalasvuori M (2013) Phage therapy: should bacterial resistance to phages be a concern, even in the long run? Bacteriophage 3:e24219. https://doi.org/10.4161/bact.24219
102. Pan Y-J, Lin T-L, Lin Y-T, Su P-A, Chen C-T, Hsieh P-F, Hsu C-R, Chen C-C, Hsieh Y-C, Wang J-T (2015) Identification of capsular types in carbapenem-resistant Klebsiella pneumoniae strains by wzc sequencing and implications for capsule depolymerase treatment. Antimicrob Agents Chemother 59:1038–1047. https://doi.org/10.1128/AAC.03560-14
103. Pastagia M, Euler C, Chahales P, Fuentes-Duculan J, Krueger JG, Fischetti VA (2011) A novel chimeric lysin shows superiority to mupirocin for skin decolonization of methicillin-resistant and sensitive Staphylococcus aureus strains. Antimicrob Agents Chemother 55:738–744. https://doi.org/10.1128/AAC.00890-10
104. Paul V, Rajagopalan S, Sundarrajan S, George SE, Asrani JY, Pillai R, Chikkamadaiah R, Durgaiah M, Sriram B, Padmanabhan S (2011) A novel bacteriophage tail-associated muralytic enzyme (TAME) from phage K and its development into a potent antistaphylococcal protein. BMC Microbiol 11:226. https://doi.org/10.1186/1471-2180-11-226
105. Pearl S, Gabay C, Kishony R, Oppenheim A, Balaban NQ (2008) Nongenetic individuality in the host–phage interaction. PLoS Biol 6:957–964. https://doi.org/10.1371/journal.pbio.0060120
106. Peng S-Y, You R-I, Lai M-J, Lin N-T, Chen L-K, Chang K-C (2017) Highly potent antimicrobial modified peptides derived from the Acinetobacter baumannii phage endolysin LysAB2. Sci Rep 7:11477. https://doi.org/10.1038/s41598-017-11832-7
107. Pires DP, Oliveira H, Melo LDR, Sillankorva S, Azeredo J (2016) Bacteriophage-encoded depolymerases: their diversity and biotechnological applications. Appl Microbiol Biotechnol 100:2141–2151. https://doi.org/10.1007/s00253-015-7247-0
108. Pirnay J-P, De Vos D, Verbeken G, Merabishvili M, Chanishvili N, Vaneechoutte M, Zizi M, Laire G, Lavigne R, Huys I, Van den Mooter G, Buckling A, Debarbieux L, Pouillot F, Azeredo J, Kutter E, Dublanchet A, Gorski A, Adamia R (2011) The phage therapy paradigm: prêt-à-porter or sur-mesure? Pharm Res 28:934–937. https://doi.org/10.1007/s11095-010-0313-5
109. Plotka M, Kaczorowska AK, Stefanska A, Morzywolek A, Fridjonsson OH, Dunin-Horkawicz S, Kozlowski L, Hreggvidsson GO, Kristjansson JK, Dabrowski S, Bujnicki JM, Kaczorowski T (2014) Novel highly thermostable endolysin from Thermus scotoductus MAT2119 bacteriophage Ph2119 with amino acid sequence similarity to eukaryotic peptidoglycan recognition proteins. Appl Environ Microbiol 80:886–895. https://doi.org/10.1128/AEM.03074-13
110. Prins JM, van Deventer SJ, Kuijper EJ, Speelman P (1994) Clinical relevance of antibiotic-induced endotoxin release. Antimicrob Agents Chemother 38:1211–1218. https://doi.org/10.1128/AAC.38.6.1211
111. Prokhorov NS, Riccio C, Zdorovenko EL, Shneider MM, Browning C, Knirel YA, Leiman PG, Letarov AV (2017) Function of bacteriophage G7C esterase tailspike in host cell adsorption. Mol Microbiol 105:385–398. https://doi.org/10.1111/mmi.13710
112. Ramachandran G (2014) Gram-positive and gram-negative bacterial toxins in sepsis. Virulence 5:213–218. https://doi.org/10.4161/viru.27024
113. Rashel M, Uchiyama J, Ujihara T, Uehara Y, Kuramoto S, Sugihara S, Yagyu K-I, Muraoka A, Sugai M, Hiramatsu K, Honke K, Matsuzaki S (2007) Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage phi MR11. J Infect Dis 196:1237–1247. https://doi.org/10.1086/521305
114. Resch G, Moreillon P, Fischetti VA (2011) A stable phage lysin (Cpl-1) dimer with increased antipneumococcal activity and decreased plasma clearance. Int J Antimicrob Agents 38:516–521. https://doi.org/10.1016/j.ijantimicag.2011.08.009
115. Rico-Lastres P, Díez-Martínez R, Iglesias-Bexiga M, Bustamante N, Aldridge C, Hesek D, Lee M, Mobashery S, Gray J, Vollmer W, García P, Menéndez M (2015) Substrate recognition and catalysis by LytB, a pneumococcal peptidoglycan hydrolase involved in virulence. Sci Rep 5:16198. https://doi.org/10.1038/srep16198
116. Roach DR, Leung CY, Henry M, Morello E, Singh D, Di Santo JP, Weitz JS, Debarbieux L (2017) Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen. Cell Host Microbe 22:38–47.e4. https://doi.org/10.1016/j.chom.2017.06.018
117. Rodríguez-Rubio L, Gerstmans H, Thorpe S, Mesnage S, Lavigne R, Briers Y (2016) DUF3380 domain from a Salmonella phage endolysin shows potent N-acetylmuramidase activity. Appl Environ Microbiol 82:4975–4981. https://doi.org/10.1128/AEM.00446-16
118. Rodríguez-Rubio L, Martínez B, Donovan DM, García P, Rodríguez A (2013) Potential of the virion-associated peptidoglycan hydrolase HydH5 and its derivative fusion proteins in milk biopreservation. PLoS One 8:e54828. https://doi.org/10.1371/journal.pone.0054828
119. Ryan EM, Gorman SP, Donnelly RF, Gilmore BF (2011) Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. J Pharm Pharmacol 63:1253–1264. https://doi.org/10.1111/j.2042-7158.2011.01324.x
120. Salmond GPC, Fineran PC (2015) A century of the phage: past, present and future. Nat Rev Microbiol 13:777–786. https://doi.org/10.1038/nrmicro3564
121. Sass P, Bierbaum G (2007) Lytic activity of recombinant bacteriophage phi11 and phi12 endolysins on whole cells and biofilms of Staphylococcus aureus. Appl Environ Microbiol 73:347–352. https://doi.org/10.1128/AEM.01616-06
122. Schirmeier E, Zimmermann P, Hofmann V, Biebl M, Gerstmans H, Maervoet VE, Briers Y (2017) Inhibitory and bactericidal effect of Artilysin® Art-175 against colistin-resistant mcr-1-positive Escherichia coli isolates. Int J Antimicrob Agents. https://doi.org/10.1016/j.ijantimicag.2017.08.027
123. Schleifer KH, Kandler O (1972) Peptidoglycan types of bacterial cell walls and their taxonomic implications. Bacteriol Rev 36:407–477
124. Schmelcher M, Donovan DM, Loessner MJ (2012a) Bacteriophage endolysins as novel antimicrobials. Future Microbiol 7:1147–1171. https://doi.org/10.2217/fmb.12.97
125. Schmelcher M, Powell AM, Becker SC, Camp MJ, Donovan DM (2012b) Chimeric phage lysins act synergistically with lysostaphin to kill mastitis-causing Staphylococcus aureus in murine mammary glands. Appl Environ Microbiol 78:2297–2305. https://doi.org/10.1128/AEM.07050-11
126. Schmelcher M, Shen Y, Nelson DC, Eugster MR, Eichenseher F, Hanke DC, Loessner MJ, Dong S, Pritchard DG, Lee JC, Becker SC, Foster-Frey J, Donovan DM (2014) Evolutionarily distinct bacteriophage endolysins featuring conserved peptidoglycan cleavage sites protect mice from MRSA infection. J Antimicrob Chemother 70:1453–1465. https://doi.org/10.1093/jac/dku552
127. Schuch R, Nelson D, Fischetti VA (2002) A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 418:884–889. https://doi.org/10.1038/nature01026
128. Shen Y, Barros M, Vennemann T, Gallagher DT, Yin Y, Linden SB, Heselpoth RD, Spencer DJ, Donovan DM, Moult J, Fischetti VA, Heinrich F, Lösche M, Nelson DC (2016) A bacteriophage endolysin that eliminates intracellular streptococci. elife 5:e13152. https://doi.org/10.7554/eLife.13152
129. Shen Y, Köller T, Kreikemeyer B, Nelson DC (2013) Rapid degradation of Streptococcus pyogenes biofilms by PlyC, a bacteriophage-encoded endolysin. J Antimicrob Chemother 68:1818–1824. https://doi.org/10.1093/jac/dkt104
130. Singh PK, Donovan DM, Kumar A (2014) Intravitreal injection of the chimeric phage endolysin Ply187 protects mice from Staphylococcus aureus endophthalmitis. Antimicrob Agents Chemother 58:4621–4629. https://doi.org/10.1128/AAC.00126-14
131. Skurnik M, Strauch E (2006) Phage therapy: Facts and fiction. Int. J. Med. Microbiol. 296:5–14. https://doi.org/10.1016/j.ijmm.2005.09.002
132. Smith J (1924) The bacteriophage in the treatment of typhoid fever. Br Med J 2:47–49
133. Son J-S, Lee S-J, Jun SY, Yoon SJ, Kang SH, Paik HR, Kang JO, Choi Y-J (2010) Antibacterial and biofilm removal activity of a podoviridae Staphylococcus aureus bacteriophage SAP-2 and a derived recombinant cell-wall-degrading enzyme. Appl Microbiol Biotechnol 86:1439–1449. https://doi.org/10.1007/s00253-009-2386-9
134. Speck P, Smithyman A (2016) Safety and efficacy of phage therapy via the intravenous route. FEMS Microbiol Lett 363:fnv242. https://doi.org/10.1093/femsle/fnv242
135. Sulakvelidze A, Alavidze Z, Morris JG Jr (2001) Bacteriophage therapy minireview. Antimicrob Agents Chemother 45:649–659. https://doi.org/10.1128/AAC.45.3.649
136. Thierauf A, Perez G, Maloy S (2009) Generalized transduction. In: Clokie MRJ, Kropinski A (eds) Bacteriophages: methods and protocols. Volume 1: isolation, characterization, and interactions. Humana press, pp 267–286
137. Totté JEE, van Doorn MB, Pasmans SGMA (2017) Successful treatment of chronic Staphylococcus aureus-related dermatoses with the topical endolysin staphefekt SA.100: a report of 3 cases. Case Rep Dermatol 9:19–25. https://doi.org/10.1159/000473872
138. van Langevelde P, Kwappenberg KM, Groeneveld PH, Mattie H, van Dissel JT (1998) Antibiotic-induced lipopolysaccharide (LPS) release from Salmonella Typhi: delay between killing by ceftazidime and imipenem and release of LPS. Antimicrob Agents Chemother 42:739–743
139. van Valen L (1973) A new evolutionary law. Evol Theory 1:1–30. https://doi.org/10.1017/CBO9781107415324.004
140. Verbeken G, Huys I, De Vos D, De Coninck A, Roseeuw D, Kets E, Vanderkelen A, Draye JP, Rose T, Jennes S, Ceulemans C, Pirnay JP (2016) Access to bacteriophage therapy: discouraging experiences from the human cell and tissue legal framework. FEMS Microbiol Lett 363:fnv241. https://doi.org/10.1093/femsle/fnv241
141. Vollmer W, Joris B, Charlier P, Foster S (2008) Bacterial peptidoglycan (murein) hydrolases. FEMS Microbiol Rev 32:259–286. https://doi.org/10.1111/j.1574-6976.2007.00099.x
142. Waseh S, Hanifi-Moghaddam P, Coleman R, Masotti M, Ryan S, Foss M, MacKenzie R, Henry M, Szymanski CM, Tanha J (2010) Orally administered P22 phage tailspike protein reduces Salmonella colonization in chickens: prospects of a novel therapy against bacterial infections. PLoS One 5:e13904. https://doi.org/10.1371/journal.pone.0013904
143. Weber-Dabrowska B, Jonczyk-Matysiak E, Zaczek M, Lobocka M, Lusiak-Szelachowska M, Gorski A (2016) Bacteriophage procurement for therapeutic purposes. Front Microbiol 7:1177. https://doi.org/10.3389/fmicb.2016.01177
144. Weiss N, Miller F, Cazaubon S, Couraud P-O (2009) The blood–brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta Biomembr 1788:842–857. https://doi.org/10.1016/j.bbamem.2008.10.022
145. Wingfield PT (2015) Overview of the purification of recombinant proteins. Curr Protoc protein Sci 80:6.1.1–6.135. https://doi.org/10.1002/0471140864.ps0601s80
146. Witzenrath M, Schmeck B, Doehn JM, Tschernig T, Zahlten J, Loeffler JM, Zemlin M, Müller H, Gutbier B, Schütte H, Hippenstiel S, Fischetti VA, Suttorp N, Rosseau S (2009) Systemic use of the endolysin Cpl-1 rescues mice with fatal pneumococcal pneumonia. Crit Care Med 37:642–649. https://doi.org/10.1097/CCM.0b013e31819586a6
147. Wommack KE, Colwell RR (2000) Virioplankton: viruses in aquatic ecosystems. Microbiol Mol Biol Rev 64:69–114. https://doi.org/10.1128/MMBR.64.1.69-114.2000
148. World Medical Association (2013) World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310:2191–2194. https://doi.org/10.1001/jama.2013.281053
149. Yang H, Wang M, Yu J, Wei H (2015) Antibacterial activity of a novel peptide-modified lysin against Acinetobacter baumannii and Pseudomonas aeruginosa. Front Microbiol 6:1471. https://doi.org/10.3389/fmicb.2015.01471
150. Yoong P, Schuch R, Nelson D, Fischetti VA (2006) PlyPH, a bacteriolytic enzyme with a broad pH range of activity and lytic action against Bacillus anthracis. J Bacteriol 188:2711–2714. https://doi.org/10.1128/JB.188.7.2711-2714.2006
151. Yoong P, Schuch R, Nelson D, Fischetti VA (2004) Identification of a broadly active phage lytic enzyme with lethal activity against antibiotic-resistant Enterococcus faecalis and Enterococcus faecium. J Bacteriol 186:4808–4812. https://doi.org/10.1128/JB.186.14.4808-4812.2004
152. Zhang L, Li D, Li X, Hu L, Cheng M, Xia F, Gong P, Wang B, Ge J, Zhang H, Cai R, Wang Y, Sun C, Feng X, Lei L, Han W, Gu J (2016) LysGH15 kills Staphylococcus aureus without being affected by the humoral immune response or inducing inflammation. Sci Rep 6:29344. https://doi.org/10.1038/srep29344